• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Sunday, June 4, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Synthetic Biology

Synthetic RNAs designed to fight cancer

Bioengineer by Bioengineer
December 6, 2013
in Synthetic Biology
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In search of better cancer treatments, researchers at Washington University School of Medicine in St. Louis have designed synthetic molecules that combine the advantages of two experimental RNA therapies.

Synthetic RNAs designed to fight cancer

RNA is closely related to DNA and plays an important role in how genes are turned on and off in the body. Both siRNAs and microRNAs are snippets of RNA known to modulate a gene’s signal or shut it down entirely. Separately, siRNA and microRNA treatment strategies are in early clinical trials against cancer, but few groups have attempted to marry the two.

“These are preliminary findings, but we have shown that the concept is worth pursuing,” said Xiaowei Wang, PhD, assistant professor of radiation oncology at the School of Medicine and a research member of the Siteman Cancer Center. “We are trying to merge two largely separate fields of RNA research and harness the advantages of both.”

The study appears in the December issue of the journal RNA.

“We designed an artificial RNA that is a combination of siRNA and microRNA,” Wang said. “Working with cancer cells in the laboratory, we showed that our artificial RNA combines the functions of the two separate molecules, simultaneously inhibiting both cell migration and proliferation.”

For therapeutic purposes, “small interfering” RNAs, or siRNAs, are designed and assembled in a lab and can be made to shut down – or interfere with – a single specific gene that drives cancer.

The siRNA molecules work extremely well at silencing a gene target because the siRNA sequence is made to perfectly complement the target sequence, thereby silencing a gene’s expression. Though siRNAs are great at turning off the gene target, they also have potentially dangerous side effects: siRNAs inadvertently can shut down other genes that need to be expressed to carry out tasks that keep the body healthy.

According to Wang and his colleagues, siRNAs interfere with off-target genes that closely complement their “seed region,” a short but important section of the siRNA sequence that governs binding to a gene target.

“We can never predict all of the toxic side effects that we might see with a particular siRNA,” said Wang. “In the past, we tried to block the seed region in an attempt to reduce the side effects. Until now, we never tried to replace the seed region completely.”

Wang and his colleagues asked whether they could replace the siRNA’s seed region with the seed region from microRNA. Unlike siRNA, microRNA is a natural part of the body’s gene expression. And it can also shut down genes. As such, the microRNA seed region (with its natural targets) might reduce the toxic side effects caused by the artificial siRNA seed region. Plus, the microRNA seed region would add a new tool to shut down other genes that also may be driving cancer.

Wang’s group started with a bioinformatics approach, using a computer algorithm to design siRNA sequences against a common driver of cancer, a gene called AKT1 that encourages uncontrolled cell division. They used the program to select siRNAs against AKT1 that also had a seed region highly similar to the seed region of a microRNA known to inhibit a cell’s ability to move, thus potentially reducing the cancer’s ability to spread. In theory, replacing the siRNA seed region with the microRNA seed region also would combine their functions – reducing cell division and movement with a single RNA molecule.

Of more than 1,000 siRNAs that can target AKT1, they found only three that each had a seed region remarkably similar to the seed region of the microRNA that reduces cell movement.

They then took the microRNA seed region and used it to replace the seed region in the three siRNAs that target AKT1. The close similarity between the two seed regions is required because changing the original siRNA sequence too much would make it less effective at shutting down AKT1.

They dubbed the resulting combination RNA molecule “artificial interfering” RNA, or aiRNA. Once they arrived at these three sequences using computer models, they actually assembled the aiRNAs and tested them in cancer cells.

One of the three artificial RNAs that they built in the lab combined the advantages of the original siRNA and the microRNA seed region that was transplanted into it. This aiRNA greatly reduced both cell division (like the siRNA) and movement (like the microRNA). And to further show proof-of-concept, they also did the reverse, designing an aiRNA that both resists chemotherapy and promotes movement of the cancer cells.

“Obviously, we would not increase cell survival and movement for cancer therapy, but we wanted to show how flexible this technology can be, potentially expanding it to treat diseases other than cancer,” Wang said.

Story Source:

The above story is based on materials provided by Washington University School of Medicine.

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Democratizing synthetic biology

March 2, 2015
blank

A new path for novel synthetic polio vaccine

February 17, 2015

New class of synthetic molecules mimics antibodies

December 19, 2014

Synthetic Molecule Makes Cancer Self-Destruct

August 12, 2014
Please login to join discussion

POPULAR NEWS

  • plants

    Plants remove cancer causing toxins from air

    40 shares
    Share 16 Tweet 10
  • Element creation in the lab deepens understanding of surface explosions on neutron stars

    36 shares
    Share 14 Tweet 9
  • Deep sea surveys detect over five thousand new species in future mining hotspot

    35 shares
    Share 14 Tweet 9
  • How life and geology worked together to forge Earth’s nutrient rich crust

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Phase 3 SWOG Cancer Research Network trial, led by a City of Hope researcher, demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy

The promise of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

Carbon-based stimuli-responsive nanomaterials: classification and application

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 50 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In